Publication | Open Access

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

Phase 2BClinical TrialsProspective EvaluationSepsisTherapeutic EfficacyInflammatory MarkerPharmacotherapySepsis PhenotypingSeptic ShockMedicine